We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 325

Patent survives anticipation attack based on use in Phase III clinical trial
  • Gowling WLG
  • Canada
  • September 22 2016

On September 7, 2016, the Federal Court found that Apotex and Cobalt infringed three claims of Bayer’s Canadian Letters Patent No. 2,382,426.1 The


Can post-Brexit UK remain involved in the UP and UPC system?
  • Gowling WLG
  • European Union, United Kingdom
  • September 16 2016

An Opinion, by English barristers Richard Gordon QC and Tom Pascoe, has been published considering the effect of Brexit (i.e. Departure from the EU


Eli Lilly's erectile dysfunction patent stands up to scrutiny
  • Gowling WLG
  • United Kingdom
  • September 1 2016

The English High Court (Patents Court) has ruled in a patent dispute concerned with the treatment of erectile dysfunction. Actavis and Mylan had


Court of Appeal confirms Genentech Herceptin formulation patents invalid
  • Gowling WLG
  • United Kingdom
  • August 30 2016

The Court of Appeal has confirmed that two Genentech patents concerning lyophilised formulations of trastuzumab (the active ingredient in Herceptin


Brexit - the impact on standard-essential patent litigation in the UK
  • Gowling WLG
  • European Union, United Kingdom
  • July 5 2016

In the week or so since the UK's Brexit vote, much has been written in Intellectual Property (IP) circles about the effect on various IP rights and


Janssen awarded damages almost 10 years after Teva found to have infringed LEVAQUIN patent
  • Gowling WLG
  • Canada
  • June 24 2016

In a recent decision of the Federal Court (Janssen Inc. v. Teva Canada Limited, 2016 FC 593), Justice Hughes awarded approximately $18 million in


Obviousness central to Federal Court’s REYATAZ (atazanavir bisulfate) decision
  • Gowling WLG
  • Canada
  • June 24 2016

In a decision dated May 27, 2016 in respect of Bristol-Myers Squibb’s (“BMS”) REYATAZ (atazanavir bisulfate), Justice Mactavish of the Federal


Post Amazon.com: How the Canadian Patent Appeal Board has dealt with patent-eligibility of computer-implemented subject matter
  • Gowling WLG
  • Canada
  • June 15 2016

Originally published on June 1, 2015 Updated on June 15, 2016 An important consideration for every patentee is that each countries’ patent system has


Applications for leave to appeal dismissed - 10 June 2016
  • Gowling WLG
  • Canada
  • June 10 2016

The applicant sought reconsideration of a decision of the Public Service Labour Relations and Employment Board (“Board”) dated February 21, 2008. She


Federal Court of Appeal affirms application of principles of causation, burden of proof and laws of evidence to section 8 proceedings
  • Gowling WLG
  • Canada
  • June 6 2016

In its recent decision, reported as Pfizer Canada Inc. v Teva Canada Limited, 2016 FCA 161, the Federal Court of Appeal ("FCA") overturned the